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Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all cancers in men and less than 1% of all diagnosed 
breast cancers.1 MBC and female breast cancer differ 
in age at diagnosis, frequency of the histological types, 
and frequency of expression of hormone receptors. The 
median age at diagnosis in men is 68 years compared 
with 63 years in women.2t4 Men with breast cancer have 
a higher occurrence of ductal histology. More than 85% 
of all cases are invasive ductal carcinomas; in women the 
frequency of ductal histology is 70% to 75%.5 Estrogen, 
androgen, and progesterone steroid receptor expression 
is also higher in MBC.5,6 Despite the biological differt
ences, the clinical outcome for breast cancer in men is 
similar to that in women when they are matched for 
age, treatment, and stage of cancer.5,7 Optimal managet
ment of MBC is not clearly established and treatment 
guidelines are scarce. The literature on male breast cant
cer consists mainly of casetcontrol and retrospective 
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studies. There are no randomized, prospective data.2 In 
this study, we retrospectively evaluated the general feat
tures, treatment, and outcome in 39 male patients folt
lowed at our clinic with the diagnosis of breast cancer 
between 1996 and 2004.
PATIENTS AND METHODS
We analyzed general characteristics and survival in 39 
male patients with a diagnosis of breast cancer who were 
treated at the radiation oncology clinic of Okmeydanı 
Training and Research State Hospital between January 
1996 and December 2004. Patient records, surgit
cal reports, pathology reports, followtup examination 
and study notes present in patient files in the clinical 
archives were examined and patients were evaluated 
in terms of age, the operation performed and its date, 
histopathologic diagnosis, stage, lymph node metastat
ses, tumor size, estrogen receptor (ER)/progesterone 
receptor (PR) status, treatments applied, recurrences 
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and survival. Patients were divided into four groups 
by age: <49 years, 50t59 years, 60t69 years and >70 
years in order to evaluate the effect of age on prognosis. 
Patients were assigned to three main groups according 
to histological diagnosis as invasive ductal carcinoma 
(IDC), invasive papillary carcinoma (IPC), and invasive 
lobular carcinoma (ILC). Staging was by the American 
Joint Committee Clinical Staging System introduced in 
2002. 
All patients received adjuvant therapy following surt
gery: 2.6% received radiotherapy (RT) alone, 5.1% RT+ 
hormonotherapy (HT), 15.4% RT+chemotherapy 
(CT), 46.1% RT+CT+HT; 10.3% of the patients ret
ceived CT alone, 7.7% HT alone and 12.8% CT+HT. 
In 29 patients, in whom the tumor size was equal and 
more than 3 cm and had no lymph node infiltration, 
radiotherapy was applied to the chest wall through tant
gential fields, 200 cGy fraction dose/25 days, a total of 
50 Gy with a Cobalt 60 device. In patients with lymph 
node involvement, 200 cGy fraction/25 days, for a total 
of 50 Gy radiotherapy was applied to the lymphatics 
in the axillary and supraclavicular areas, in addition to 
the chest wall irradiation. Radiotherapy was not apt
plied to 4 patients who had metastases at the beginning 
and to 2 patients who did not accept treatment. Apart 
from these, all patients received standard radiotherapy 
regardless of the number of lymph nodes involved. 
Infiltration radiotherapy was not performed in patients 
with a tumor size of 3 cm or less and with no lymph 
node involvement.
In three patients, chemotherapy was performed bet
cause of lymph node infiltration, receptor negativity 
and the presence of metastases. Chemotherapy protot
cols used were CMF, FEC, EC and AC (A=adriamycin, 
C=cyclophosphamide, E=epirubicine, F=5tfluorourat
cil, M=methotrexate). FEC was used in 10 patients 
(25.6%), FAC in 2 (5.1%), CM in 9 (23.1%), EC in 9 
(23.1%), AC in 1 (2.6%), and CMF+FAC in 2 (5.1%). 
TMX (tamoxifen) was used in all the patients schedt
uled for hormonotherapy. 
SPSS (Statistical Package for Social Sciences) for 
Windows 10.0 program was used for statistical analyt
sis to evaluate the results. In addition to the descript
tive statistics (median, standard deviation, frequency), a 
onetway ANOVA test was used for comparing groups 
with parameters showing normal distribution in quant
titative data and the Tukey HDS test was used to det
termine the group that accounted for the difference. For 
qualitative data, the chitsquare test and Fisher exact test 
were used. KaplantMeier survival analysis was used for 
survival analyses and the log rank test was used for comt
paring survival data. For multiple evaluations, the Cox 
regression test was used. 
RESULTS
Three (7.7%) patients were lost during followtup aft
ter treatment. The median followtup was 59 months 
(range, 13t122 months). Thirtytnine cases are included 
in our study. The mean age was 58 years (range, 33t79) 
and mean followtup time was 59 months (range, 13t
122). The most frequent symptom before diagnosis 
was a mass in the breast, and the second most frequent 
symptom was gynecomastia. The tumor was localized 
on the right side in 46.2% of patients and in the left 
side in 53.8% (Table 1). Twentytnine (74.4%) patients 
had lymph node involvement. In the 33 (85%) cases 
in which receptor analysis was performed, the ER was 
positive in 22 patients. In 24 patients the PR was posit
tive. IDC was diagnosed in 37 patients, IPC in 1 pat
tient and ILC in 1 patient. In 23 patients (58.9%) the 
surgical intervention was MRM+AK (modified radit
cal mastectomy+axillary curettage), and in 16 patients 
(41.1%) it was SM+AK (simple mastectomy+axillary 
curettage). Treatment modality by stage is shown in 
Table 2. At presentation, there were distant metastat
ses in 4 patients (3 bone metastases, 1 bone + pulmot
nary metastasis), and 4 had skin invasions. Statistical 
evaluation of the patient characteristics showed that 
the frequency of IDC was statistically significant in 
comparison to the other histological types (P<.001). 
Also, the number of patients with a tumor size of 2t5 
cm (P<.01), the number of patients with lymph node 
involvement (P<.001) and receptor positivity (P=.009) 
was significantly higher. There was no statistical differt
ence regarding left or right breast localizations (P>.05), 
age distribution (P>.05) and stage (P>.05). 
Recurrences and Metastases
During the median followtup period of 59 months 
(range, 13t122 months), local recurrence was found 
in 2 patients (5.1%), and metastases in 14 patients 
(35.9%) (Table 3). One of the recurrences developed 
during followtup in a patient that already had metat
static disease at presentation, and the other in 1 patient, 
26 months after surgery, during the radiotherapy course 
of CRT+HT. The distant metastases in 14 (35.9%) 
patients were found to be single or multiple organ met
tastases; 20.5% had pulmonary metastases, 5.1% liver 
metastases, 25.6% bone metastases, 2.6% brain metast
tases; of these, 4 (10.3%) had only pulmonary metastat
ses, 3 (7.7%) only bone metastases, 4 (10.3%) bone + 
pulmonary metastases, 2 (5.1%) bone + liver metastat
ses and 1 (2.6%) bone + pulmonary + brain metastases. 
Thirteen of the patients (33.3%) died; 23 (58.9%) were 
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still alive at the time of writing, while the outcome of 3 
of the patients (7.7%) was unknown.
Survival
Survival ranged between 13 to 122 months, with the 
mean (±standard deviation) for overall survival (OS) 
time of 89.1±6.8 months. Diseasetfree survival (DFS) 
also ranged between 13 to 122 months with a mean of 
87.7±7.7 months (Figure 1, 2). The 2tyear  disease free 
survival (DFS) and OS rates were 87.2% and 89.7%, 
respectively, and the 5tyear DFS and OS rates were 
65.8% and 80.1%, respectively. In the univariate analysis 
of factors such as lymph node involvement, stage, age, 
tumor size and the inclusion of radiotherapy in treatt
ment, all of which are considered significant for OS, it 
was found that lymph node involvement (P=.00001), 
stage (P=.0098), age (P=.0339) were statistically signift
icant, whereas tumor size (P=.4439) and radiotherapy 
(P=.6849) had no significant effect on OS. 
In patients with lymph node stage N0, the 2t and 5t 
year OS rate was 100%. Mean survival was 114.7±5.9 
months. In lymph node stage N1, 2tyear OS was 
95.4±04.4%. The 5tyear OS rate was 79.9±9.1%, with a 
mean survival time of 81.7±6.3 months. In lymph node 
stage N2, the 2t and 5tyear OS rate was 66.7±27.2%, 
with a mean survival time of 66 months. In lymph node 
stage N3 the 2t and 5tyear OS rate was 25.0±21.6%, 
and mean survival time was 24.0±4.1 months. There 
was a significant difference between lymph node int
volvement and OS time (log rank=27.16; P=.00001; 
P<.05). In N0 cases the OS was significantly longer, 
and in N3 cases significantly shorter (Figure 3). 
In Stage I patients the 2t and 5tyear OS rate was 
100%. In Stage II patients the 2tyear OS rate was 
94.4±5.4%. The 5tyear OS rate was 87.2±8.6%, with 
a mean survival time of 95.6±8.2 months. In Stage III 
cases the 2t and 5tyear OS rate was 83.3±10.8%. Mean 
survival was 77.7±9.2 months. In Stage IV cases the 
2tyear DFS rate was 75.0±21.6%, the 5tyear OS was 
25.0±21.6% and the mean survival time was 37.3±8.63 
months. There was a significant difference in OS rates 
for the stages (log rank=11.39; P=.0098; P<0.05) 
(Figure 4).
In the 0t49tyear age group, the 2t and 5tyear OS rate 
was 85.7±13.2%; the mean OS rate was 72.86±12.19 
months. In the 50t59tyear age group, the 2tyear OS 
rate was 86.7±08.8%, the 5tyear OS was 74.3±13.7%, 
and the mean survival was 95.2±10.9 months. In the 
60t69tyear age group, the 2t and 5tyear OS rate was 
90.9±08.7% and the mean OS was 99.4±6.3 months. 
In patients older than 70 years, the 2tyear OS was 
83.3±15.2%, the 5tyear OS was 62.5±21.4%, and the 
Table 1. patient characteristics.
Patient characteristics n % P
Tumor settling 
P>.05right 18 46.2
left 21 53.8
Histology
P<.001
invasive ductal carcinoma 37 94.9
invasive papiller carcinoma 1 2.6
invasive lobuler carcinoma 1 2.6
Surgery
P>.05MrM+Ak 23 58.9
SM+Ak 16 41.1
Lymph node status 
P<.001positive 29 74.4
negative 10 25.6
Receptor Status
P=.009estrogen 22 56.4
progesterone 24 61.5
Age
P>.05
0-49 8 20.5
50-59 14 35.9
60-69 11 28.2
70+ 6 15.4
Stage
P>.05
i 5 12.8
iiA 9 23.1
iib 9 23.1
iiiA 3 7.7
iiib 7 17.9
iiiC 2 5.1
iV 4 10.3
Tumor size
P<.001
< 2 cm 11 28.2
2-5 cm 22 56.4
≥ 5 cm 6 15.4
Lymph node
P<.001
n0 10 25.6
n1 22 56.4
n2 3 7.7
n3 4 10.3
MrM+Ak = modified radical masectomy + auxillary curettage. SM+Ak = simple masectomy + auxillary curettage.
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Table 2.  Distribution of patients according to stages and treatment modalities.
Treatment Modality
S±HT S+RT±HT S+CT±HT S+RT+CT±HT
Stage
n % n % n % n %
I 3 60 - - 2 40 - -
II - - 3    17.6 2    11.8 12     70.6
III - - - - 1 7.7 12     92.3
IV - - - - 4 100 - -
S: surgery, HT: hormonotherapy, rT: radiotherapy, CT: chemotherapy
Table 3. Site of recurrence after type of treatment.
Stage Treatment No. of patients NED Local Recurrence
Distant 
Metasteses Local+Distant
i S±HT 3 3 - - -
S+rT±HT - - - - -
S+CT±HT 2 2 - - -
S±C+rT±HT - - - - -
ii S±HT - - - - -
S+rT±HT 3 2 - 1 -
S+CT±HT 2 2 - - -
S±C+rT±HT 12 8 - 3 1
iii S±HT - - - - -
S+rT±HT - - - - -
S+CT±HT 1 1 - - -
S±C+rT±HT 12 7 - 5 -
iV S±HT - - - - -
S+rT±HT - - - - -
S+CT±HT 4 - - 3 1
S±C+rT±HT - - - - -
S: surgery, rT: radiotherapy, CT: chemotherapy, HT: hormonotherapy, neD: no evidence of disease
mean survival was 53.2±8.5 months. There was a sigt
nificant difference in OS rates by age (log rank=8.68; 
P=.0339; P<.05). OS was significantly lower in the 
younger age groups in particular (Figure 5).
In patients with a tumor size smaller than 2 cm, 
the 2t and 5tyear OS was 100%. Mean survival was 
88.0±6.5 months. For tumor sizes between 2t5 cm, 
the 2tyear OS rate was 84.0±7.3%. The 5tyear OS rate 
was 68.3±10.3% and the mean survival was 82.9±8.7 
months. In tumor sizes 5 cm and larger, the 2tyear OS 
was 100%. The 5tyear OS rate was 80.0±17.9% and 
mean survival time was 85.3±9.9 months. There was 
no significant difference in OS rate by tumor size (log 
rank=1.62; P=.4439; P>.05) (Figure 6).
 In patients who did not receive radiotherapy, the 2t
year OS was 100%. The 5tyear OS rate was 78.8±13.4% 
and mean survival was 70.2 months. In patients who 
received radiotherapy, the 2tyear OS was 85.7±6.6%. 
The 5tyear OS rate was 80.9±7.8% and mean survival 
time was 87.6 months. There was no significant differt
ence in OS time between patients who received radiot
therapy and who did not (log rank=0.16; P=.6849; 
P>.05) (Figure 7). When the variables in the univariate 
analysis were evaluated by the multivariate Cox regrest
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Figure 1. Overall survival.
Figure 2. Disease-free survival
Figure 3. univariate analysis of overall survival by lymph node 
metastases.
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sion analysis, only lymph node involvement showed a 
statistically significant difference in both OS (P=.004) 
and DFS (P=.014) (Table 4,5 ). 
DISCUSSION
Although breast cancer is seen more frequently in the 
early premenopausal period in women, the frequency 
in men increases with age, with a mean age of approxit
mately 68 years reported by different studies.2t4 The 
mean age of our study cases was 58 years. In another 
study performed in our center, the mean age was ret
ported as 60 years.8 The lower mean age compared with 
other countries can be related to the lifetexpectancy of 
63t65 years in our society. 
Histopathologic differences between women and 
men are due to the fact that the classic lobular structure 
does not develop in men. As the male breast does not 
have lobular elements, the most frequently encountered 
male breast cancer type is IDC (85%t90%).5 Our study 
results were similar, with a ratio of 94.9% for IDC, and 
this was significantly higher than the other histological 
types. Ductal carcinoma in situ (DCIS), was found in 
5% and up to 17%t20% in some series of male breast 
cancers.9t11 While IDC was found to be 94.9% in our 
study and was similar to other studies, we had no pat
tients with DCIS, possibly because patients in our 
society usually are not referred to a health center until 
they have main complaints; in addition, breast cancer is 
considered a cancer specific to females. 
Estrogen receptor positivity is more frequent in men 
with breast cancer, in comparison to women. In differt
ent studies, ER and progesterone receptor (PR) positivt
ity was reported as 75%t93%.5,6 In our study, receptor 
analysis was performed in 33 (85%) patients. In pat
tients analyzed for receptors, ER was positive in 66.6% 
(22 patients), and PR in 73% (24 patients). While PR 
frequency was similar to that reported in the literature, 
the ER ratio was slightly lower. 
In most studies, axillary lymphadenopathy indicatt
ing possible metastases based on clinical grounds was 
present in 40% to 55% of the patients at the time of 
referral, but histologic axillary node metastases was 
found in 60%.4,9,21 In our study, axillary lymph node met
tastases were found in 74.4% (29 patients). The stage 
of involvement was mostly N1 (N1=56.4%, N2=7.7%, 
N3=10.3%) The 15% higher ratio for axillary involvet
ment was due to the late referral to physicians because of 
social moral values. Similarly, in other studies, the stage 
in patients at referral according to the TNM system 
was stage 0:0%t10%; stage 1:10%t40%; stage II: 15%t
45%; stage III: 20%t50%; stage IV: 5%t15%. However, 
in our study these ratios were at the upper levels of ret
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Figure 4. univariate analysis of overall survival by stage (P=.0098).
Figure 5.  univariate analysis of overall survival by age (P=.0339).
Figure 6. univariate analysis of overall survival by tumor size 
(P>.05).
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Figure 7. univariate analysis of overall survival by presence of 
radiotherapy (P=.6849, rT vs no rT).
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ported limits like, stage I:12%t32%; stage II:46.15%; 
stage III: 30.76%; stage IV:10.25%.12,13 The 5tyear 
OS rates reported in the literature are stage I:80%t
100%; stage II:44%t70%; stage III:16%t62% and stage 
IV:0%t12%.4,10,22 The results of our study were stage 
I:100%; stage II:87±8%; stage III:83±10% and stage 
IV:25±21% and similar to the literature.8,13t16
 Breast cancer in men is treated using the same stratt
egy as in women. Although no consensus is reached ret
garding localtregional therapy in male breast cancer,9 
in disease localized to the breast and axillary nodes, 
primary therapy is mastectomy together with axillary 
dissection.17,18 In previous studies, radical mastectomy 
was preferred, since the rational for this was the localt
ization of the lesion near to the pectoralis major muscle 
and the tumor being in a more advanced stage in men 
compared to women at the time of diagnosis.12,19 Recent 
studies favor modified radical or simple mastectomy 
combined with radiation therapy.12,20 There seems to 
be no prominent difference in survival between radical 
mastectomy and other methods.12 In our study, modit
fied radical mastectomy was performed in 59% of the 
patients and simple mastectomy in 41% and no differt
ence was observed in survival.
Postoperative radiotherapy does achieve local cont
trol, but no effect is observed on survival.16 In men 
treated with mastectomy, adjuvant radiotherapy det
creased local recurrence. Indications for therapy det
pend on local findings. Radiotherapy is performed in 
tumors involving the skin and chest wall. Involvement 
of the skin and nipple is more frequent in men than in 
women. This condition may be related to breast size 
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Table 5. Multivariate analysis of  disease-free survival.
   Variate B SE Wald df P value Exp (B)
95% CI for Exp (B)
 
Lower Upper
   Stage 0.480 0.521 0.847 1 0.357 1.616 0.582 4.489
   Tumor size -0.175 0.553 0.100 1 0.752 0.840 0.284 2.480
   Age -0.640 0.340 3.544 1 0.060 0.527 0.271 1.027
   lymph node 
   metastases 1.138 0.461 6.093 1 0.014 3.121 1.264 7.707
   radiotherapy 0.009 0.896 0.000 1 0.992 1.009 0.174 5.846
Table 4. Multivariate analysis of overall survival. 
   Variate B SE Wald df P value Exp(B)
   95% CI for Exp(B)
Lower Upper
   Tumor size -0.691 0.536 1.663 1 0.197 0.501 0.175 1.432
   Stage 0.595 0.539 1.219 1 0.270 1.813 0.631 5.211
   Age -0.263 0.329 0.637 1 0.425 0.769 0.403 1.466
   radiotherapy -1.129 1.049 1.159 1 0.282 0.323 0.041 2.526
   lymph node
   metastases 1.575 0.549 8.239 1 0.004 4.831 1.648 14.161
and proximity of the tumor to these structures.18 In 
our series, 27 (69.23%) patients received radiotherapy, 
and local recurrence was seen in one (3.7%) of the 22 
patients that received postoperative radiotherapy and 
in one (8.3%) of 12 patients that did not. When mean 
5tyear OS and DFS between groups that did and did 
not receive radiotherapy were compared, no signifit
cant difference was found, but patients in the RT arm 
survived longer. Mean DFS in the RT group was 82.7 
months, whereas in the group without RT it was 68.5 
months. Mean OS in the RT group was 87.6 months, 
while in the group without RT it was 70.2 months. RT 
was usually used in advanced stage patients. The simit
larity in survival rates between groups with and witht
out radiotherapy can be taken as an indication that the 
contribution of radiotherapy to DFS and OS was an 
increase in local control.
 The rate of axillary lymph node metastases in male 
breast cancer is reported as 55% in various series; in our 
study this ratio was 74%. In many studies, DFS and 
OS are significantly longer in patients without lymph 
node involvement.18 In line with this, the 5tyear DFS 
and OS in our study in patients without lymph node 
involvement was 100%. The mean survival in N0 was 
114 months, which decreased to 81 months in N1; 66 
months in N2; and 24 months in N3. Therefore, it can 
be stated that lymph node involvement was the most imt
portant prognostic factor. With systemic therapy added 
to the treatment of the patients with axillary lymph 
node involvement, better survival results were obtained 
in patients that received systemic therapy than in the 
patients who did not. Frequently used chemotherapy 
regimens were CMF, FEC and EC. In our study 84.6% 
of the patients received adjuvant chemotherapy. There 
was no difference in DFS and OS rates between the 
chemotherapy regimens used. 
 Different results are reported for OS and DFS rates 
in relation to tumor size, but the consensus is that larger 
tumors have a poor prognosis.21 However, in our study 
there was no significant correlation between tumor size 
and survival. This could be due to the small number of 
people with big tumors and the presence of other progt
nostic factors in these patients. Guinee and friends,18 in 
their study comprising 335 cases, showed that clinical 
axillary lymph node involvement as well as clinical tut
mor size had a role in prognosis. In our study, in both 
univariate and multivariate analysis, a positive correlat
tion was established only between axillary lymph node 
involvement and recurrence and OS, but no correlation 
was found for tumor size. Life expectancy in men with 
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breast cancer is worse than in women. While some int
vestigators explain this as due to the more aggressive 
biologic behavior of MBC, a more common explanat
tion is the rareness of MBC and resultant diagnosis at 
a more advanced stage.9,22 The public should be made 
aware that breast cancer can be seen in men as well.
In conclusion, in MBC, lymph node involvement is 
frequent because of late referral. Lymph node involvet
ment is the most important prognostic factor in both 
OS and DFS. Adding postoperative radiotherapy to 
treatment does increase local control but has no effect 
on survival. 
